Literature DB >> 24455898

[The phenomenon of release activity and the hypothesis of "spatial" homeostasis].

O I Epstein.   

Abstract

When analyzing the technology of multiple sequential reductions in concentration of parent substance we have discovered a novel physical phenomenon. It was shown that dilutions of parent substance prepared using this technology have one common peculiarity - they are capable to exert direct modifying effect on parent substance altering spatial structure of parent substance and consequently its physical, chemical and biological properties. Technologically processed dilutions also exert activity when they do not contain molecules of parent substance. We have defined a newly revealed modifying activity manifested in the process of multiple sequential reductions in concentrations and associated with vehicle as release-activity while the drugs exerting modifying activity we have called release-active drugs. Having analyzed the ceffects of a drug in the whole range of doses - toxic, therapeutic, low doses as well as release-active form of a drug we came to a conclusion that there were supramolecular spatial matrices with the structure, which was identical to the one of a certain substance, and combines body molecules into semantic molecular assemblies. All biological systems unlike nonliving nature have dual structure - both individual and specific ones. Enhancement in any body spatial complexity is its key feature from the point of view of evolution development; that is why all processes - both normal physiologic and pathologic ones - shall comply with superiority of preservation of a body spatial structure hierarchy (hypothesis of spatial homeostasis).

Mesh:

Substances:

Year:  2013        PMID: 24455898

Source DB:  PubMed          Journal:  Usp Fiziol Nauk        ISSN: 0301-1798


  6 in total

1.  Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin.

Authors:  E A Gorbunov; J Nicoll; E V Kachaeva; S A Tarasov; O I Epstein
Journal:  Nutr Diabetes       Date:  2015-07-06       Impact factor: 5.097

2.  IVIG ameliorate inflammation in collagen-induced arthritis: projection for IVIG therapy in rheumatoid arthritis.

Authors:  G Halpert; I Katz; M Blank; O Shovman; S Tarasov; K K Ganina; N Petrova; M Tocut; A Volkov; I Barshack; H Amital
Journal:  Clin Exp Immunol       Date:  2020-10-26       Impact factor: 5.732

3.  Novel approach to activity evaluation for release-active forms of anti-interferon-gamma antibodies based on enzyme-linked immunoassay.

Authors:  Elena S Gavrilova; Sergey A Bobrovnik; Gordon Sherriff; Andrey A Myslivets; Sergey A Tarasov; Oleg I Epstein
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

4.  Use of Piezoelectric Immunosensors for Detection of Interferon-Gamma Interaction with Specific Antibodies in the Presence of Released-Active Forms of Antibodies to Interferon-Gamma.

Authors:  Elena Don; Olga Farafonova; Suzanna Pokhil; Darya Barykina; Marina Nikiforova; Darya Shulga; Alena Borshcheva; Sergey Tarasov; Tatyana Ermolaeva; Oleg Epstein
Journal:  Sensors (Basel)       Date:  2016-01-20       Impact factor: 3.576

5.  In vitro screening of major neurotransmitter systems possibly involved in the mechanism of action of antibodies to S100 protein in released-active form.

Authors:  Evgeniy A Gorbunov; Irina A Ertuzun; Evgeniya V Kachaeva; Sergey A Tarasov; Oleg I Epstein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-11-03       Impact factor: 2.570

6.  Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial.

Authors:  Dmitry Pushkar; Andrey Vinarov; Leonid Spivak; Konstantin Kolontarev; Mikhail Putilovskiy; Elena Andrianova; Oleg Epstein
Journal:  Cent European J Urol       Date:  2018-12-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.